To verify RAS-driven degradation and the cause-and-effect link between RAS degradation and drug efficacy, we first observed the degradation of KRAS G12D in SW1990 cells but not KRAS G12C in MIA PaCa-2 human pancreatic cancer cells (homozygous KRAS G12C) (Figure 5A). Here, KRAS is linked to familial pancreatic carcinoma.